Mankind Pharma’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. Standalone revenue from operations reached ₹2,608.78 crores. The company’s profit before tax from continuing operations was ₹524.63 crores. Basic EPS from continuing operations stood at ₹11.12. The board also declared that they’re in compliance with the Debenture Trust Deed.
Financial Performance Highlights
The Board of Directors of Mankind Pharma has officially approved the financial results for Q2, 2025. Here are some of the key figures from the standalone results:
- Revenue from Operations: ₹2,608.78 crores
- Other Income: ₹77.67 crores
- Profit Before Tax from Continuing Operations: ₹524.63 crores
- Current Tax: ₹97.54 crores
- Deferred Tax: (₹31.81) crores
- Basic EPS from Continuing Operations: ₹11.12
Consolidated Performance Overview
The Board also reviewed consolidated financial results. The key figures are:
- Revenue from Operations: ₹3,697.16 crores
- Other Income: ₹91.87 crores
- Profit Before Tax: ₹624.02 crores
- Basic EPS from Continuing Operations: ₹12.39
Additional Key Updates
In addition to approving the financial results, the board has also confirmed that the company remains compliant with all financial covenants as specified in the Debenture Trust Deed.
Investments in Subsidiaries
During Q2 2025, Mankind Pharma made strategic investments in several subsidiaries:
- Lifestar Pharmaceuticals Private Limited: Invested in equity shares.
- Mankind Life Sciences Private Limited: Invested in 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares.
- Mankind Agritech Private Limited: Invested in 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares.
- Mankind Medicare Private Limited: Invested in 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares.
- Mankind Prime Labs Private Limited: Invested in 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares.
These investments are intended to expand Mankind Pharma’s reach and capabilities across various healthcare segments.
Source: BSE
